Cyclosporine versus tacrolimus (FK 506) for prevention of cardiac allograft vasculopathy

V Klauss; A König; C Spes; B Meiser; J Rieber; U Siebert; E Regar; M Pfeiffer; B Reichart; K Theisen; H Mudra

doi:10.1016/s0002-9149(99)00631-1

Cyclosporine versus tacrolimus (FK 506) for prevention of cardiac allograft vasculopathy

Am J Cardiol. 2000 Jan 15;85(2):266-9. doi: 10.1016/s0002-9149(99)00631-1.

Authors

V Klauss¹, A König, C Spes, B Meiser, J Rieber, U Siebert, E Regar, M Pfeiffer, B Reichart, K Theisen, H Mudra

Affiliation

¹ Department of Internal Medicine, Klinikum Innenstadt, University of Munich, Germany.

PMID: 10955391
DOI: 10.1016/s0002-9149(99)00631-1

Abstract

This study prospectively compared the impact of cyclosporine A and tacrolimus on the development of cardiac allograft vasculopathy. By using serial intravascular ultrasound examinations, a trend toward a more pronounced progression was noted in the tacrolimus group in the first year after heart transplantation.

Publication types

Clinical Trial
Randomized Controlled Trial

MeSH terms

Adolescent
Adult
Aged
Coronary Disease / diagnostic imaging
Coronary Disease / etiology
Coronary Disease / prevention & control*
Cyclosporine / therapeutic use*
Female
Follow-Up Studies
Heart Transplantation / adverse effects*
Humans
Immunosuppressive Agents / therapeutic use*
Male
Middle Aged
Tacrolimus / therapeutic use*
Ultrasonography

Substances

Immunosuppressive Agents
Cyclosporine
Tacrolimus